The Effect of Different Intervention Approaches on Gross Motor Outcomes of Children With Autism Spectrum Disorder: A Meta-Analysis

2019 ◽  
Vol 36 (4) ◽  
pp. 501-526 ◽  
Author(s):  
Layne Case ◽  
Joonkoo Yun

Despite the rising interest in intervention for children with autism spectrum disorder, the extent to which interventions are effective on gross motor outcomes is currently unknown. The purpose of this study was to analyze the effect of different intervention approaches on gross motor outcomes among children with autism spectrum disorder using meta-analysis. A total of 18 studies met the inclusion criteria for quantitative analysis. Pre- and posttest means and SD s were extracted to calculate effect sizes. Potential moderator variables were chosen based on important intervention characteristics. The results suggest that interventions have a large effect on gross motor outcomes among children with autism spectrum disorder (δ = 0.99, SE  = 0.19, p  < .001, 95% confidence interval [0.62, 1.36]). The interventions that were 16 total hours or longer had a significantly larger effect than those less than 16 hr. In addition, the interventions in experimental settings had significantly larger effects than the interventions in practical settings. Future interventions should consider intensity, including not only the duration of the intervention but also the intensity in which specific intervention goals are targeted.

2021 ◽  
Vol 11 (6) ◽  
pp. 488
Author(s):  
Daniel A Rossignol ◽  
Richard E Frye

Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting approximately 2% of children in the United States. Growing evidence suggests that immune dysregulation is associated with ASD. One immunomodulatory treatment that has been studied in ASD is intravenous immunoglobulins (IVIG). This systematic review and meta-analysis examined the studies which assessed immunoglobulin G (IgG) concentrations and the therapeutic use of IVIG for individuals with ASD. Twelve studies that examined IgG levels suggested abnormalities in total IgG and IgG 4 subclass concentrations, with concentrations in these IgGs related to aberrant behavior and social impairments, respectively. Meta-analysis supported possible subsets of children with ASD with low total IgG and elevated IgG 4 subclass but also found significant variability among studies. A total of 27 publications reported treating individuals with ASD using IVIG, including four prospective, controlled studies (one was a double-blind, placebo-controlled study); six prospective, uncontrolled studies; 2 retrospective, controlled studies; and 15 retrospective, uncontrolled studies. In some studies, clinical improvements were observed in communication, irritability, hyperactivity, cognition, attention, social interaction, eye contact, echolalia, speech, response to commands, drowsiness, decreased activity and in some cases, the complete resolution of ASD symptoms. Several studies reported some loss of these improvements when IVIG was stopped. Meta-analysis combining the aberrant behavior checklist outcome from two studies demonstrated that IVIG treatment was significantly associated with improvements in total aberrant behavior and irritability (with large effect sizes), and hyperactivity and social withdrawal (with medium effect sizes). Several studies reported improvements in pro-inflammatory cytokines (including TNF-alpha). Six studies reported improvements in seizures with IVIG (including patients with refractory seizures), with one study reporting a worsening of seizures when IVIG was stopped. Other studies demonstrated improvements in recurrent infections, appetite, weight gain, neuropathy, dysautonomia, and gastrointestinal symptoms. Adverse events were generally limited but included headaches, vomiting, worsening behaviors, anxiety, fever, nausea, fatigue, and rash. Many studies were limited by the lack of standardized objective outcome measures. IVIG is a promising and potentially effective treatment for symptoms in individuals with ASD; further research is needed to provide solid evidence of efficacy and determine the subset of children with ASD who may best respond to this treatment as well as to investigate biomarkers which might help identify responsive candidates.


2019 ◽  
Vol 42 ◽  
pp. 104-113 ◽  
Author(s):  
Tomasz Trzmiel ◽  
Barbara Purandare ◽  
Michał Michalak ◽  
Ewa Zasadzka ◽  
Mariola Pawlaczyk

2020 ◽  
Vol 18 (2) ◽  
pp. 203-213
Author(s):  
Liyao Song ◽  
Xiaomei Luo ◽  
Qing Jiang ◽  
Zhi Chen ◽  
Lifang Zhou ◽  
...  

2019 ◽  
Vol 7 (1) ◽  
pp. 91-118 ◽  
Author(s):  
Cally Kent ◽  
Reinie Cordier ◽  
Annette Joosten ◽  
Sarah Wilkes-Gillan ◽  
Anita Bundy ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0224362 ◽  
Author(s):  
Sadiq Naveed ◽  
Ahmed Waqas ◽  
Afshan Naz Amray ◽  
Raheel Imtiaz Memon ◽  
Nisma Javed ◽  
...  

2020 ◽  
Vol 51 ◽  
pp. 430-445
Author(s):  
Álvaro Bejarano-Martín ◽  
Ricardo Canal-Bedia ◽  
María Magán-Maganto ◽  
Clara Fernández-Álvarez ◽  
Sigrídur Lóa-Jónsdóttir ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document